Cystic Fibrosis is a rare inherited disorder that causes loss of lung function and damages the digestive system. It has a higher prevalence in the Caucasian population. For years there was no treatment available targeting the underlying cause, however, this changed in 2012 with the launch of Vertex Pharma’s Kalydec...
Find MoreVertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.